Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Tumor Virus Infections

ClinicalTrials.gov lists 2,028 trials for Tumor Virus Infections or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 148.

MeSH D014412 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 449 Phase 1/2 Phase 1/2 199 Phase 2 Phase 2 470 Phase 2/3 Phase 2/3 25 Phase 3 Phase 3 216 Phase 4 Phase 4 56 Not applicable Not applicable 292 Observational Observational 313 Phase 1 Phase 1 449 Phase 1/2 Phase 1/2 199 Phase 2 Phase 2 470 Phase 2/3 Phase 2/3 25 Phase 3 Phase 3 216 Phase 4 Phase 4 56 Not applicable Not applicable 292 Observational Observational 313

Trials per phase

2 more sections with rows

10 of the 2,028 trials are tagged with Tumor Virus Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Tumor Virus Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Tumor Virus Infections trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 115

1990: 4 trials (Not applicable 1, Phase 2 3) 1991: 2 trials (Phase 2 2) 1992: 9 trials (Observational 2, Phase 3 1, Phase 2 5, Phase 1 1) 1993: 5 trials (Observational 1, Phase 2 3, Phase 1 1) 1994: 5 trials (Observational 1, Phase 2 2, Phase 1 2) 1995: 11 trials (Observational 1, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 3) 1996: 17 trials (Observational 5, Phase 2 6, Phase 1 6) 1997: 30 trials (Not applicable 2, Phase 3 6, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 10) 1998: 37 trials (Not applicable 1, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 17, Phase 1/2 3, Phase 1 12) 1999: 49 trials (Observational 2, Not applicable 3, Phase 3 6, Phase 2 10, Phase 1/2 5, Phase 1 23) 2000: 50 trials (Observational 2, Not applicable 4, Phase 3 5, Phase 2 20, Phase 1/2 3, Phase 1 16) 2001: 28 trials (Observational 1, Not applicable 3, Phase 3 5, Phase 2 9, Phase 1/2 1, Phase 1 9) 2002: 43 trials (Observational 3, Not applicable 4, Phase 4 2, Phase 3 7, Phase 2 10, Phase 1/2 2, Phase 1 15) 2003: 44 trials (Observational 4, Not applicable 6, Phase 3 6, Phase 2 13, Phase 1/2 6, Phase 1 9) 2004: 60 trials (Observational 1, Not applicable 7, Phase 3 10, Phase 2 21, Phase 1/2 3, Phase 1 18) 2005: 55 trials (Observational 7, Not applicable 6, Phase 4 1, Phase 3 6, Phase 2 18, Phase 1/2 5, Phase 1 12) 2006: 55 trials (Observational 8, Not applicable 3, Phase 4 1, Phase 3 8, Phase 2 18, Phase 1/2 3, Phase 1 14) 2007: 81 trials (Other 1, Observational 14, Not applicable 8, Phase 4 1, Phase 3 17, Phase 2 16, Phase 1/2 5, Phase 1 19) 2008: 59 trials (Observational 16, Not applicable 4, Phase 3 14, Phase 2 10, Phase 1/2 4, Phase 1 11) 2009: 65 trials (Other 1, Observational 17, Not applicable 7, Phase 4 3, Phase 3 13, Phase 2 10, Phase 1/2 2, Phase 1 12) 2010: 67 trials (Observational 22, Not applicable 8, Phase 4 5, Phase 3 3, Phase 2/3 2, Phase 2 14, Phase 1/2 3, Phase 1 10) 2011: 57 trials (Observational 10, Not applicable 6, Phase 4 2, Phase 3 13, Phase 2/3 1, Phase 2 12, Phase 1/2 4, Phase 1 9) 2012: 48 trials (Observational 13, Not applicable 9, Phase 3 5, Phase 2 8, Phase 1/2 6, Phase 1 7) 2013: 43 trials (Observational 5, Not applicable 5, Phase 3 2, Phase 2/3 1, Phase 2 11, Phase 1/2 5, Phase 1 14) 2014: 51 trials (Observational 3, Not applicable 7, Phase 4 1, Phase 3 6, Phase 2/3 3, Phase 2 14, Phase 1/2 7, Phase 1 10) 2015: 55 trials (Observational 9, Not applicable 7, Phase 4 2, Phase 3 4, Phase 2 22, Phase 1/2 6, Phase 1 5) 2016: 58 trials (Observational 6, Not applicable 11, Phase 4 1, Phase 3 1, Phase 2/3 2, Phase 2 15, Phase 1/2 7, Phase 1 15) 2017: 73 trials (Observational 9, Not applicable 6, Phase 4 2, Phase 3 7, Phase 2 21, Phase 1/2 11, Phase 1 17) 2018: 65 trials (Observational 7, Not applicable 10, Phase 4 2, Phase 3 5, Phase 2 18, Phase 1/2 9, Phase 1 14) 2019: 88 trials (Observational 9, Not applicable 15, Phase 3 11, Phase 2 18, Phase 1/2 10, Phase 1 25) 2020: 86 trials (Observational 15, Not applicable 12, Phase 4 7, Phase 3 9, Phase 2/3 1, Phase 2 15, Phase 1/2 7, Phase 1 20) 2021: 91 trials (Observational 19, Not applicable 11, Phase 4 7, Phase 3 10, Phase 2/3 2, Phase 2 15, Phase 1/2 11, Phase 1 16) 2022: 115 trials (Observational 22, Not applicable 24, Phase 4 8, Phase 3 10, Phase 2/3 2, Phase 2 16, Phase 1/2 15, Phase 1 18) 2023: 99 trials (Observational 24, Not applicable 18, Phase 4 4, Phase 3 5, Phase 2 17, Phase 1/2 10, Phase 1 21) 2024: 90 trials (Observational 27, Not applicable 28, Phase 4 1, Phase 3 1, Phase 2/3 3, Phase 2 9, Phase 1/2 10, Phase 1 11) 2025: 107 trials (Observational 15, Not applicable 28, Phase 4 2, Phase 3 7, Phase 2/3 4, Phase 2 14, Phase 1/2 14, Phase 1 23)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 93
2025 107
2024 90
2023 99
2022 115
2021 91
2020 86
2019 88
2018 65
2017 73

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 100 trials starting in 2026 and about 100 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 227 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 1,236 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Tumor Virus Infections trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 449
Phase 1/2 199
Phase 2 470
Phase 2/3 25
Phase 3 216
Phase 4 56
Not applicable 292
Observational 313
Expanded access 7
Unknown 1

How many Tumor Virus Infections trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 85
Recruiting 257
Enrolling by invitation 8
Active, not recruiting 138
Available 3

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Tumor Virus Infections trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 148
GlaxoSmithKline 72
Merck Sharp & Dohme LLC 54
Children's Oncology Group 25
National Institute of Allergy and Infectious Diseases (NIAID) 19

Which drugs are being tested for Tumor Virus Infections? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 225
RITUXIMAB 113
Prednisone 67

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 123
Etoposid 99
Peripheral blood stem cell transplantation 93
Filgrastime (G-CSF) 90
HD- Methotrexate (MTX) 87

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Tumor Virus Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Neutrophil count decreased 1,100 35
Platelet count decreased 876 32
Febrile neutropenia 869 68
White blood cell decreased 731 18
Anemia 532 36

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Tumor Virus Infections? (234)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
BK Nephropathy in the Modern Era: What Have We Learned? Kidney360 2025 Yes
Insights from the BKEVER Trial comparing everolimus versus mycophenolate mofetil for BK Polyomavirus infection in kidney transplant recipients. Kidney international 2025 Yes
A highly potent human antibody neutralizing all serotypes of BK polyomavirus. PLoS pathogens 2025 Yes
Interventions for BK virus infection in kidney transplant recipients. The Cochrane database of systematic reviews 2024 Yes
The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation. Transplantation 2024 Yes

Showing 5 of 234 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages